Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

Rachel Sacks-Davis,Daniela K van Santen,Anders Boyd,Jim Young,Ashleigh Stewart,Joseph S Doyle,Andri Rauch,Catrina Mugglin,Marina Klein,Marc van der Valk,Colette Smit,Inmaculada Jarrin,Juan Berenguer,Karine Lacombe,Maria-Bernarda Requena,Linda Wittkop,Olivier Leleux,Fabrice Bonnet,Dominique Salmon,Gail V Matthews,Rebecca Guy,Natasha K Martin,Tim Spelman,Maria Prins,Mark Stoove,Margaret Hellard,InCHEHC Collaboration,Margaret E Hellard,Rachel Sacks-Davis,Daniela K van Santen,Ashleigh Stewart,Tianhui Ke,Yanqin Zhang,Mark Stoove,Rebecca Guy,Alisa Pedrana,Jason Asselin,Joshua Dawe,Anna Wilkinson,Anders Boyd,Colette Smit,Marc van der Valk,Janke Schinkel,Linda Wittkop,Dominique Salmon,Philippe Sogni,Laure Esterle,Camille Gilbert,Laurence Merchadou,Stephanie Gillet,Coralie Khan,Fabrice Bonnet,Olivier Leleux,Fabien Le Marec,Adelaide Perrier,Gail Matthews,Ineke Shaw,Marianne Martinello,Tanya Applegate,Joanne Carson,Joseph S Doyle,Brendan Harney,Melissa Bryant,Inmaculada Jarrin Vera,Juan Berenguer,Belen Alejos,Jeffrey V Lazarus,Cristina Moreno,Rebecca Izquierdo,Marta Rava,Marina Klein,Shouao Wang,Jessica Lumia,Costa Pexos,Hansi Peiris,Sahar Saeed,Erica Moodie,Jim Young,Neora Pick,Brian Conway,Mark Hull,Alex Wong,John Gill,Lisa Barrett,Jeff Cohen,Joseph Cox,Pierre Cote,Shariq Haider,Danielle Rouleau,Marie-Louise Vachon,Anita Rachlis,Roger Sandre,Sharon Walmsley,Aida Sadr,Curtis Cooper,Steve Sanche,Andri Rauch,Catrina Mugglin,Luisa Salazar-Viscaya,Katharina Kusejko,Maria Prins,Kris Hage,Karine Lacombe,Maria-Bernada Requena,Pierre-Marie Girard,Matthieu Brucker,Jean-Paul Vincensini

DOI: https://doi.org/10.1016/s2352-3018(23)00267-9

IF: 16.07

2024-02-01

The Lancet HIV

Abstract:BACKGROUND: Reinfection after successful treatment with direct-acting antivirals is hypothesised to undermine efforts to eliminate hepatitis C virus (HCV) infection among people with HIV. We aimed to assess changes in incidence of HCV reinfection among people with HIV following the introduction of direct-acting antivirals, and the proportion of all incident cases attributable to reinfection.METHODS: We pooled individual-level data on HCV reinfection in people with HIV after spontaneous or treatment-induced clearance of HCV from six cohorts contributing data to the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC) in Australia, Canada, France, the Netherlands, Spain, and Switzerland between Jan 1, 2010, and Dec 31, 2019. Participants were eligible if they had evidence of an HCV infection (HCV antibody or RNA positive test) followed by spontaneous clearance or treatment-induced clearance, with at least one HCV RNA test after clearance enabling measurement of reinfection. We assessed differences in first reinfection incidence between direct-acting antiviral access periods (pre-direct-acting antiviral, limited access [access restricted to people with moderate or severe liver disease and other priority groups], and broad access [access for all patients with chronic HCV]) using Poisson regression. We estimated changes in combined HCV incidence (primary and reinfection) and the relative contribution of infection type by calendar year.FINDINGS: Overall, 6144 people with HIV who were at risk of HCV reinfection (median age 49 years [IQR 42-54]; 4989 [81%] male; 2836 [46%] men who have sex with men; 2360 [38%] people who inject drugs) were followed up for 17 303 person-years and were included in this analysis. The incidence of first HCV reinfection was stable during the period before the introduction of direct-acting antivirals (pre-introduction period; 4·1 cases per 100 person-years, 95% CI 2·8-6·0). Compared with the pre-introduction period, the average incidence of reinfection was 4% lower during the period of limited access (incidence rate ratio [IRR] 0·96, 95% CI 0·78-1·19), and 28% lower during the period of broad access (0·72, 0·60-0·86). Between 2015 and 2019, the proportion of incident HCV infections due to reinfection increased, but combined incidence declined by 34%, from 1·02 cases per 100 person-years (95% CI 0·96-1·07) in 2015 to 0·67 cases per 100 person-years (95% CI 0·59-0·75) in 2019.INTERPRETATION: HCV reinfection incidence and combined incidence declined in people with HIV following direct-acting antiviral introduction, suggesting reinfection has not affected elimination efforts among people with HIV in InCHEHC countries. The proportion of incident HCV cases due to reinfection was highest during periods of broad access to direct-acting antivirals, highlighting the importance of reducing ongoing risks and continuing testing in people at risk.FUNDING: Australian National Health and Medical Research Council.

immunology,infectious diseases